Exscientia plc (EXAI)

Market Cap	587.03M
Revenue (ttm)	25.42M
Net Income (ttm)	-184.76M
Shares Out	125.70M
EPS (ttm)	-1.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,841
Open	5.21
Previous Close	5.09
Day's Range	4.67 - 5.24
52-Week Range	3.86 - 9.12
Beta	0.78
Analysts	Buy
Price Target	9.75 (+91.55%)
Earnings Date	May 22, 2024

About EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2021
• Employees: 483
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAI

Financial Performance

In 2023, Exscientia's revenue was 20.08 million, a decrease of -26.24% compared to the previous year's 27.22 million. Losses were -145.96 million, 22.9% more than in 2022.

Financial numbers in GBP

Analyst Forecast

According to 4 analysts, the average rating for EXAI stock is "Buy." The 12-month stock price forecast is $9.75, which is an increase of 91.55% from the latest price.

Price Target

$9.75

(91.55% upside)

Analyst Consensus: Buy